IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells (Q34636880)

3 August 2017

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells (English)

1 reference

chronic lymphocytic leukemia

3 August 2017

0 references

1 reference

1 reference

1 reference

8

John C Byrd

1 reference

3 August 2017

Shuai Dong

1

1 reference

3 August 2017

Daphne Guinn

2

1 reference

3 August 2017

Jason A Dubovsky

3

1 reference

3 August 2017

Yiming Zhong

4

1 reference

3 August 2017

Amy Lehman

5

1 reference

3 August 2017

Jeffery Kutok

6

1 reference

3 August 2017

Jennifer A Woyach

7

1 reference

3 August 2017

Amy J Johnson

9

1 reference

3 August 2017

language of work or name

English

0 references

publication date

25 September 2014

1 reference

3 August 2017

1 reference

3 August 2017

124

1 reference

3 August 2017

24

1 reference

3 August 2017

3583-3586

1 reference

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

The B-cell receptor signaling pathway as a therapeutic target in CLL.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4256910

10.1182/BLOOD-2014-07-587279

26 October 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

3 August 2017

1 reference